Management of antibody-mediated rejection in transplantation

Surgical Clinics of North America

Volumn 93, Issue 6, 2013, Pages 1451-1466

  Sadaka, Basma ^a   Alloway, Rita R ^a   Woodle, E Steve ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Antibody mediated rejection; Donor specific antibodies; Kidney transplantation; Plasma cell

Indexed keywords

BORTEZOMIB; COMPLEMENT COMPONENT C4D; ECULIZUMAB; HEMOGLOBIN; HLA ANTIBODY; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; STAPHYLOCOCCUS PROTEIN A; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; ANEMIA; ANTIBODY MEDIATED REJECTION; ANTIBODY PRODUCTION; ANTIINFLAMMATORY ACTIVITY; COMPLEMENT ACTIVATION; COMPLEMENT DEPENDENT CYTOTOXICITY; CREATININE BLOOD LEVEL; FIBRIN DEPOSITION; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOADSORPTION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT REJECTION; KIDNEY TRANSPLANTATION; MICROVASCULATURE; MONONUCLEAR CELL; MULTIPLE MYELOMA; NAUSEA; NEUTROPENIA; NEUTROPHIL CHEMOTAXIS; ORGAN TRANSPLANTATION; PERIPHERAL NEUROPATHY; PLASMA CELL; PLASMAPHERESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SALVAGE THERAPY; SPLENECTOMY; THROMBOCYTOPENIA; VOMITING;

ANTIBODY-MEDIATED REJECTION; DONOR-SPECIFIC ANTIBODIES; KIDNEY TRANSPLANTATION; PLASMA CELL;

ANTIBODIES; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BORONIC ACIDS; GRAFT REJECTION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; IMMUNOSORBENT TECHNIQUES; KIDNEY TRANSPLANTATION; PLASMA CELLS; PLASMAPHERESIS; PYRAZINES; SPLENECTOMY;

EID: 84887251495     PISSN: 00396109     EISSN: 15583171     Source Type: Journal    
DOI: 10.1016/j.suc.2013.08.002     Document Type: Review

References (68)

1. Mao Q., Terasaki P.I., Cai J., et al. Extremely high association between appearance of HLA antibodies and failure of kidney grafts in a five-year longitudinal study. Am J Transplant 2007, 7:864-871.
2. Lee P.C., Zhu L., Terasaki P.I., et al. HLA-specific antibodies developed in the first year posttransplant are predictive of chronic rejection and renal graft loss. Transplantation 2009, 88:568-574.
3. Mauiyyedi S., Colvin R.B. Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment. Curr Opin Nephrol Hypertens 2002, 11:609-618.
4. Lederer S.R., Friedrich N., Banas B., et al. Effects of mycophenolate mofetil on donor-specific antibody formation in renal transplantation. Clin Transplant 2005, 19(2):168-174.
5. Lucas J.G., Co J.P., Nwaogwugwu U.T., et al. Antibody-mediated rejection in kidney transplantation: an update. Expert Opin Pharmacother 2011, 12(4):579-592.
6. Sadaka B., Alloway R.R., Woodle E.S. Clinical and investigational use of proteasome inhibitors for transplant rejection. Expert Opin Investig Drugs 2011, 20(11):1535-1542.
7. Takemoto S.K., Zeevi A., Feng S., et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004, 4:1033-1041.
8. Everly M.J., Everly J.J., Arend L.J., et al. Reducing de novo donor-specific antibody levels during acute rejection diminishes renal allograft loss. Am J Transplant 2009, 9:1063-1071.
9. Ramos E.J., Pollinger H.S., Stegall M.D., et al. The effect of desensitization protocols on human splenic B-cell populations invivo. Am J Transplant 2007, 7:402-407.
10. Perry D.K., Burns J.M., Pollinger H.S., et al. Proteasome inhibition causes apoptosis of normal human plasma cells preventing alloantibody production. Am J Transplant 2009, 9:201-209.
11. Everly M.J., Everly J.J., Susskind B., et al. Bortezomib provides effective therapy for antibody- and cell-mediated acute rejection. Transplantation 2008, 86:1754-1761.
12. Walsh R.C., Everly J.J., Brailey P., et al. Proteasome inhibitor-based primary therapy for antibody-mediated renal allograft rejection. Transplantation 2010, 89:277-284.
13. Solez K., Colvin R.B., Racusen L.C., et al. Banff 07 classification of renal allograft pathology: updates and future directions. Am J Transplant 2008, 8:753-760.
14. Halloran P.F., de Freitas D.G., Einecke G., et al. An integrated view of molecular changes, histopathology and outcomes in kidney transplants. Am J Transplant 2010, 10(10):2223-2230.
15. Colvin R.B. Pathology of chronic humoral rejection. Contrib Nephrol 2009, 162:75-86.
16. Haas M., Montgomery R.A., Segave D.L., et al. Subclinical acute antibody-mediated rejection in positive crossmatch renal allografts. Am J Transplant 2007, 7:576-585.
17. Gloor J.M., Cosio F.G., Rea D.J., et al. Histologic findings one year after positive crossmatch or ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2006, 6:1841-1847.
18. Loupy A., Suberbielle-Boissel C., Hill G.S., et al. Outcome of subclinical antibody-mediated rejection in kidney transplant recipients with preformed donor-specific antibodies. Am J Transplant 2009, 9:2561-2570.
19. Roberts D.M., Jian S.H., Chadban S.J. The treatment of acute antibody-mediated rejection in kidney transplant recipients-a systematic review. Transplantation 2012, 94:775-783.
20. Singh N., Pirsch J., Samaniego M. Antibody mediated rejection: treatment alternatives and outcome. Transplant Rev (Orlando) 2009, 23(1):34-46.
21. Sureshkumar K.K., Hussain S.M., Carpenter B.J., et al. Antibody-mediated rejection following renal transplantation. Expert Opin Pharmacother 2007, 8(7):913-921.
22. Ahmed T., Senzel L. The role of therapeutic apheresis in the treatment of acute antibody-mediated kidney rejection. JClin Apher 2012, 27(4):173-177.
23. Rocha P.N., Butterly D.W., Greenberg A., et al. Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection. Transplantation 2003, 75(9):1490-1495.
24. Kirubakaran M.G., Disney A.P., Norman J., et al. Acontrolled trial of plasmapheresis in the treatment of renal allograft rejection. Transplantation 1981, 32(2):164-165.
25. Bonomini V., Vangelista A., Frasca G.M., et al. Effects of plasmapheresis in renal transplant rejection. A controlled study. Trans Am Soc Artif Intern Organs 1985, 31:698-703.
26. Allen N.H., Dyer P., Geoghegan T., et al. Plasma exchange in acute renal allograft rejection. A controlled trial. Transplantation 1983, 35(5):425-428.
27. Pascual M., Saidman S., Tolkoff-Rubin N., et al. Plasma exchange and tacrolimus-mycophenolate rescue for acute humoral rejection in kidney transplantation. Transplantation 1998, 66:1460-1464.
28. Tyden G., Kumlien G., Efvergren M. Present techniques for antibody removal. Transplantation 2007, 84:S27-S29.
29. Böhmig G.A., Wahrmann M., Reagele H., et al. Immunoadsorption in severe C4d-positive acute kidney allograft rejection: a randomized controlled trial. Am J Transplant 2007, 7(1):117-121.
30. Min L., Shuming G., Zheng T., et al. Novel rescue therapy for C4d-positive acute humoral renal allograft rejection. Clin Transplant 2005, 19(1):51-55.
31. Kihm L.P., Zeier M., Morath C. Emerging drugs for the treatment of transplant rejection. Expert Opin Emerg Drugs 2011, 16(4):683-695.
32. Kazatchkine M.D., Kaveri S.V. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. NEngl J Med 2001, 345:747-755.
33. Nimmerjahn F., Ravetch J.V. Anti-inflammatory actions of intravenous immunoglobulin. Annu Rev Immunol 2008, 26:513-533.
34. Vani J., Elluru S., Negi V., et al. Role of natural antibodies in immune homeostasis: IVIg perspective. Autoimmun Rev 2008, 7(6):440-444.
35. Luke P.P., Scantlebury V.P., Jordan M.L., et al. IVIG rescue therapy in renal transplantation. Transplant Proc 2001, 33:1093-1094.
36. Jordan S., Quartel A.W., Czer L.S., et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 1998, 66(6):800-805.
37. Lefaucheur C., Nochy D., Andrade J., et al. Comparison of combination plasmapheresis/IVIg/anti-CD20 versus high-dose IVIg in the treatment of antibody-mediated rejection. Am J Transplant 2009, 9(5):1099-1107.
38. Clynes R.A., Towers T.L., Presta L.G., et al. Inhibitory Fc receptors modulate invivo cytotoxicity against tumor targets. Nat Med 2000, 6:443-446.
39. Weiner G.J. Rituximab: mechanism of action. Semin Hematol 2010, 47:115-123.
40. Becker Y.T., Becker B.N., Pirsch J.D., et al. Rituximab as treatment for refractory kidney transplant rejection. Am J Transplant 2004, 4:996-1001.
41. Kaposztas Z., Podder H., Mauiyyedi S., et al. Impact of rituximab therapy for treatment of acute humoral rejection. Clin Transplant 2009, 23:63-73.
42. Mulley W.R., Hudson F.J., Tait B.D., et al. Asingle low-fixed dose of rituximab to salvage renal transplants from refractory antibody-mediated rejection. Transplantation 2009, 87:286-289.
43. Velcade [package insert]. Cambridge, MA: Millennium Pharmaceuticals, Inc; 2013.
44. Everly J.J., Walsh R.C., Alloway R.R., et al. Proteasome inhibition for antibody-mediated rejection. Curr Opin Organ Transplant 2009, 14:662-666.
45. Kloetzel P.M., Ossendorp F. Proteasome and peptidase function in MHC-class I-mediated antigen presentation. Curr Opin Immunol 2004, 16:76-81.
46. Kim R., Emi M., Tanabe K., et al. Role of the unfolded protein response in cell death. Apoptosis 2006, 11:5-13.
47. Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev 2003, 29(Suppl 1):3-9.
48. Walsh R.C., Brailey P., Girnita A., et al. Early and late acute antibody-mediated rejection differs immunologically and in response to proteasome inhibition. Transplantation 2011, 91(11):1218-1226.
49. Basadonna G.P., Matas A.J., Gillingham K.J., et al. Early versus late acute renal allograft rejection: impact on chronic rejection. Transplantation 1993, 55:993-995.
50. Sipkens Y.W., Doxidis I.I., Mallat M.J., et al. Early versus late acute rejection episodes in renal transplantation. Transplantation 2004, 75:204-208.
51. Dörje C., Midtvedt K., Holdaas H., et al. Early versus late acute antibody-mediated rejection in renal transplant recipients. Transplantation 2013, 96(1):79-84.
52. Flechner S.M., Fatica R., Askar M., et al. The role of proteasome inhibition with bortezomib in the treatment of antibody-mediated rejection after kidney-only or kidney-combined organ transplantation. Transplantation 2010, 90:1486-1492.
53. Schmidt N., Alloway R.R., Walsh R.C., et al. Prospective evaluation of the toxicity profile of proteasome inhibitor-based therapy in renal transplant candidates and recipients. Transplantation 2012, 94(4):352-361.
54. Almadrones L., McGuire D.B., Walczak J.R., et al. Psychometric evaluation of two scales assessing functional status and peripheral neuropathy associated with chemotherapy for ovarian cancer: a gynecologic oncology group study. Oncol Nurs Forum 2004, 31(3):615-623.
55. Richardson P.G., Sonneveld P., Schuster M.W., et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. NEngl J Med 2005, 352(24):2487-2498.
56. Orlowski R.Z., Nagler A., Sonneveld P., et al. Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression. JClin Oncol 2007, 25(25):3892-3901.
57. Stegall M.D., Chedid M.F., Cornell L.D. The role of complement in antibody-mediated rejection in kidney transplantation. Nat Rev Nephrol 2012, 8:670-678.
58. González-Roncero F., Suñer M., Bernal G., et al. Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: case reports. Transplant Proc 2012, 44:2690-2694.
59. Hillmen P., Young N.S., Schubert J., et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. NEngl J Med 2006, 355:1233-1243.
60. Locke J.E., Magro C.M., Singer A.L., et al. The use of antibody to complement protein C5 for salvage treatment of severe antibody-mediated rejection. Am J Transplant 2009, 9:231-235.
61. Stegall M.D., Diwan T., Raghavaiah S., et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011, 11:2405-2413.
62. Locke J.E., Zachary A.A., Haas M., et al. The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection. Am J Transplant 2007, 7:842-846.
63. Kaplan B., Gangemi A., Thielke J., et al. Successful rescue of refractory, severe antibody mediated rejection with splenectomy. Transplantation 2007, 83(1):99-100.
64. Roberti I., Geffner S., Vyas S. Successful rescue of refractory acute antibody-mediated renal allograft rejection with splenectomy-a case report. Pediatr Transplant 2012, 16(2):E49-E52.
65. Vo A.A., Lukovsky M., Toyoda M., et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. NEngl J Med 2008, 359:242-251.
66. Fehr T., Rusi B., Fischer A., et al. Rituximab and intravenous immunoglobulin treatment of chronic antibody-mediated kidney allograft rejection. Transplantation 2009, 87(12):1837-1841.
67. Billing H., Rieger S., Ovens J., et al. Successful treatment of chronic antibody-mediated rejection with IVIg and rituximab in pediatric renal transplant recipients. Transplantation 2008, 86(9):1214-1221.
68. Archdeacon P., Chan M., Neuland C., et al. Summary of FDA antibody-mediated rejection workshop. Am J Transplant 2011, 11:896-906.